Goldman Sachs
ALGS icon

Goldman Sachs’s Aligos Therapeutics ALGS Stock Holding History

Goldman Sachs’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-10,231
Closed -$73.8K – 6310
2025
Q2 		$73.8K Buy
+10,231
New +$61.2K ﹤0.01% 5872
2022
Q4 		– Sell
-562
Closed -$15K – 5957
2022
Q3 		$15K Sell
562
-3,396
-86% -$113K ﹤0.01% 5979
2022
Q2 		$120K Sell
3,958
-1,288
-25% -$43.8K ﹤0.01% 5808
2022
Q1 		$282K Buy
5,246
+4,063
+343% +$325K ﹤0.01% 5695
2021
Q4 		$351K Buy
1,183
+234
+25% +$85.4K ﹤0.01% 5587
2021
Q3 		$368K Sell
949
-570
-38% -$225K ﹤0.01% 5375
2021
Q2 		$774K Sell
1,519
-152
-9% -$96.9K ﹤0.01% 4952
2021
Q1 		$950K Buy
+1,671
New +$1.11M ﹤0.01% 4654

Other funds holding ALGS

WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
RAM
Readystate Asset Management Chicago, Illinois $2.23B AUM 15% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Goldman Sachs's ALGS Position: Q3 2025 in Review

Goldman Sachs sold out of Aligos Therapeutics (ALGS) in Q3 2025, closing a stake of 10,231 shares — an estimated $73.8K sold.

Goldman Sachs first reported a position in ALGS in Q1 2021 and held it in 8 quarters. The position peaked at $950K in Q1 2021. 33 funds tracked by Wall St. Rank hold ALGS as of Q3 2025.

  • Goldman Sachs reported no remaining Aligos Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Goldman Sachs sold 10,231 Aligos Therapeutics shares in Q3 2025, an estimated $73.8K.
  • Goldman Sachs first reported a position in Aligos Therapeutics in Q1 2021 and held it in 8 quarters.
  • Goldman Sachs's Aligos Therapeutics position peaked at $950K in Q1 2021.
  • 33 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q3 2025.

Based on Goldman Sachs's 13F filing for Q3 2025, filed 14 Nov 2025.